BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35323348)

  • 1. Delivering Chemotherapy to a Metastatic Poor Risk Testicular Cancer Patient on Hemodialysis.
    Moore KJ; Snow S; Wood LA
    Curr Oncol; 2022 Mar; 29(3):1808-1812. PubMed ID: 35323348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.
    Kundu SD; Feldman DR; Carver BS; Gupta A; Bosl GJ; Motzer RJ; Bajorin DF; Sheinfeld J
    J Urol; 2015 Feb; 193(2):513-8. PubMed ID: 25150639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer.
    Kawai K; Akaza H
    Cancer Sci; 2010 Jan; 101(1):22-8. PubMed ID: 19922501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful chemotherapy for advanced nonseminomatous germ-cell tumor in a patient undergoing chronic hemodialysis.
    Froehner M; Passauer J; Schuler U; Hakenberg OW; Wirth MP
    J Clin Oncol; 2007 Apr; 25(10):1282-4. PubMed ID: 17401020
    [No Abstract]   [Full Text] [Related]  

  • 11. Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer.
    Mezvrishvili Z; Managadze L
    Int Urol Nephrol; 2006; 38(3-4):621-4. PubMed ID: 17111082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
    Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
    J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin and etoposide for metastatic testis cancer in a renal transplant recipient.
    Vogelzang NJ
    J Urol; 1990 Jun; 143(6):1235-6. PubMed ID: 2160550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Treatment of metastatic germ cell tumor in a newly diagnosed HIV infected man: use of BEP chemotherapy.
    Mtonga P; Mwafulirwa K; Nyirenda R; Masamba L
    Malawi Med J; 2011 Sep; 23(3):91-3. PubMed ID: 23448004
    [No Abstract]   [Full Text] [Related]  

  • 15. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
    Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
    Culine S; Kerbrat P; Kramar A; Théodore C; Chevreau C; Geoffrois L; Bui NB; Pény J; Caty A; Delva R; Biron P; Fizazi K; Bouzy J; Droz JP;
    Ann Oncol; 2007 May; 18(5):917-24. PubMed ID: 17351252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full-dose cisplatin chemotherapy combined with hemodialysis in a patient with impaired renal function and a mediastinal germ cell tumor.
    Jager NGL; Sari V; Westermann AM; Bijleveld YA; Bijlsma JA
    Anticancer Drugs; 2020 Oct; 31(9):983-987. PubMed ID: 32011365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.
    Horwich A; Dearnaley DP; Nicholls J; Jay G; Mason M; Harland S; Peckham MJ; Hendry WF
    J Clin Oncol; 1991 Jan; 9(1):62-9. PubMed ID: 1702147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy for metastatic germ cell tumours of the testis].
    Culine S
    Rev Prat; 2007 Feb; 57(4):385-8. PubMed ID: 17455740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One cycle of bleomycin, etoposide and cisplatin plus two cycles of etopeside and cisplatin chemotherapy in selected patients with low-volume stage II nonseminomatous germ cell tumor of the testis.
    Mezvrishvili Z; Managadze L
    Urol Int; 2005; 75(4):304-8. PubMed ID: 16327295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.